Recent literature suggests that AR is emerging as a interesting target for breast cancer therapy in ER-/AR+ tumors and some triple negative breast cancers (TNBCs), which are enriched for AR signalling pathways [12,61]. Here, ESR1 is linked to triple-negative breast carcinoma.